Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

@article{Svendsen2004DoesTC,
  title={Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial},
  author={K. Svendsen and T. Jensen and F. Bach},
  journal={BMJ : British Medical Journal},
  year={2004},
  volume={329},
  pages={253}
}
  • K. Svendsen, T. Jensen, F. Bach
  • Published 2004
  • Medicine
  • BMJ : British Medical Journal
  • Abstract Objective To evaluate the effect of the oral synthetic δ-9-tetrahydrocannabinol dronabinol on central neuropathic pain in patients with multiple sclerosis. Design Randomised double blind placebo controlled crossovertrial. Setting Outpatient clinic, University Hospital of Aarhus, Denmark. Participants 24 patients aged between 23 and 55 years with multiple sclerosis and central pain. Intervention Orally administered dronabinol at a maximum doseof 10 mg daily or corresponding placebo for… CONTINUE READING
    395 Citations
    What is a crossover trial?
    • 20
    A randomized, placebo‐controlled trial of levetiracetam in central pain in multiple sclerosis
    • 28
    A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis.
    • 8
    • PDF
    Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
    • 167
    • PDF
    Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial
    • 361
    • PDF
    Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
    • 308
    • PDF

    References

    SHOWING 1-10 OF 57 REFERENCES
    Pain relief with oral cannabinoids in familial Mediterranean fever
    • 122